Epigenetics/Translational Biomarkers (ETB) Core

$286,928P01FY2013CANIH

Oregon State University, Corvallis OR

Investigators

Linked publications & trials

Paper 34933053 Paper 33842408 Paper 33809839 Paper 33676582 Paper 33403784 Paper 33277315 Paper 32938017 Paper 30947707 Paper 30643017 Paper 29924908 Paper 29377494 Paper 28582660 Paper 28289824 Paper 28218467 Paper 28131897 Paper 27935856 Paper 27860235 Paper 27706811 Paper 27539959 Paper 27494294 Paper 27061150 Paper 27028006 Paper 26990437 Paper 26658879 Paper 26643866 Paper 26640761 Paper 26511489 Paper 26503773 Paper 26458818 Paper 26398937 Paper 26388957 Paper 26329135 Paper 26303421 Paper 26108801 Paper 26049101 Paper 26042194 Paper 25908611 Paper 25868132 Paper 25522265 Paper 25321483 Paper 25044704 Paper 24466240 Paper 23815143 Paper 23800833 Paper 23770684 Paper 23566957 Paper 23447562 Paper 23006636 Paper 22935520 Paper 22865632 Paper 22800507 Paper 22651935 Paper 22641368 Paper 22514694 Paper 22350780 Paper 22332092 Paper 22303414 Paper 22247744 Paper 22085489 Paper 22079312 Paper 21928849 Paper 21816223 Paper 21764279 Paper 21739482 Paper 21682828 Paper 21681606 Paper 21624135 Paper 21599534 Paper 21474954 Paper 21374800 Paper 21251982 Paper 20801632 Paper 20715105 Paper 20691268 Paper 20436256 Paper 20361925 Paper 20233842 Paper 19952359 Paper 19839593 Paper 19812222 Paper 19744467 Paper 19585502 Paper 19584079 Paper 19528666 Paper 19376641 Paper 19197985 Paper 19138945 Paper 19073876 Paper 18951251 Paper 18848954 Paper 18673487 Paper 18635525 Paper 18628250 Paper 18616682 Paper 18598138 Paper 18504070 Paper 18283038 Paper 18197554 Paper 18069110 Paper 17979099

Abstract

Epigenetics is a priority area in the NIH Roadmap. The Epigenetic/Translational Biomarkers (ETB) core has the overall goal of consolidating and applying standard methods to detect epigenetic modifications, for use in preclinical models and translational studies on Projects 1-3 of the P01. This core integrates with all three projects on the P01, with specific emphasis on methodologies and services that will be used most heavily and routinely throughout the 5-year course of investigation. This core evolved out of the prior Services Core and retains several key elements, such as the histopathology and biostatistics components. However, it now incorporates several epigenetic assays of importance to the central hypothesis of the P01: The CENTRAL HYPOTHESIS is that sulforaphane (SFN), indole-3-carbinol (I3C), and cruciferous vegetables from which they derive are effective chemopreventive agents because, in addition to their blocking activities, they alter the pattern of histone modifications and histone deacetylase (HDAC) activity in cancer cells, as well as DNA promoter methylation status, thereby de-repressing epigenetically silenced genes that regulate the ceil cycle and apoptosis. Based on the central hypothesis, the following broad specific aims will be implemented in the ETB core: Aim 1. Provide histopathology expertise for preclinical studies in rats and mice (Projects 1-3), and immunohistochemical analyses of epigenetic biomarkers (acetylated histones, HDACs) in animal and human tissues. The latter analyses will include tissue microarrays from translational studies with prostate cancer patients and colonoscopy patients. Aim 2. Conduct routine HDAC activity assays on tissues from preclinical and clinical studies (Projects 1-3). Aim 3. Run DNA methylation assays for epigenetically silenced genes of mutual interest (Projects 1-3). Arm 4. Perform LC/MS/MS analyses of SFN and I3C metabolites in tissues and body fluids (Projects 1-3). Aim 5. Coordinate protocol design and statistical analyses of data (Projects 1-3). The long-term goal is to better understand which assays and biomarker(s) for epigenetic alterations in cancers might be applied in a reliable and robust manner in the clinical setting.

View original record on NIH RePORTER →